NBIX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $67,398,545.45

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$154.63

▲ +0.411 (0.27%)

As of 12/5/2025 11:31 AM ET

Days: 30 | 90 | 365

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2025	George J Morrow	Director	Sell	15,000	$143.37	$2,150,550.00	7,068
11/5/2025	William H. Rastetter	Director	Sell	18,000	$151.82	$2,732,760.00	40,360
11/4/2025	Kyle Gano	CEO	Sell	300	$141.97	$42,591.00	140,407
8/7/2025	Kevin Charles Gorman	Director	Sell	106,322	$126.41	$13,440,164.02	514,596
7/10/2025	Ingrid Delaet	Insider	Sell	457	$135.00	$61,695.00	4,730
7/9/2025	Jude Onyia	Insider	Sell	59,819	$130.46	$7,803,986.74	18,289
7/2/2025	Jude Onyia	Insider	Sell	20,362	$130.13	$2,649,707.06	18,289
5/27/2025	Kevin Charles Gorman	Director	Sell	9,613	$120.38	$1,157,212.94	514,596
5/5/2025	William H. Rastetter	Director	Sell	30,000	$110.20	$3,306,000.00	37,491
2/13/2025	Julie Cooke	Insider	Sell	1,551	$116.78	$181,125.78	19,544
2/13/2025	Kevin Charles Gorman	Director	Sell	5,844	$116.69	$681,936.36	521,618
2/13/2025	Matt Abernethy	CFO	Sell	2,558	$116.86	$298,927.88	34,775
2/10/2025	Julie Cooke	Insider	Sell	700	$118.28	$82,796.00	18,831
2/10/2025	Kevin Charles Gorman	Director	Sell	2,274	$118.37	$269,173.38	519,074
2/10/2025	Kyle Gano	CEO	Sell	980	$118.39	$116,022.20	137,658
2/3/2025	Ingrid Delaet	Insider	Sell	623	$149.29	$93,007.67	3,442
1/31/2025	Julie Cooke	Insider	Sell	1,740	$152.89	$266,028.60	18,202
1/31/2025	Kevin Charles Gorman	Director	Sell	2,707	$152.92	$413,954.44	517,030
1/31/2025	Kyle Gano	CEO	Sell	1,541	$152.87	$235,572.67	136,778
1/31/2025	Matt Abernethy	CFO	Sell	1,283	$152.87	$196,132.21	32,681
1/27/2025	Kevin Charles Gorman	Director	Sell	146,105	$149.46	$21,836,853.30	514,596
1/15/2025	Kyle Gano	CEO	Sell	65,000	$141.50	$9,197,500.00	135,392
12/31/2024	Ingrid Delaet	Insider	Sell	272	$138.10	$37,563.20	2,507
12/17/2024	Ingrid Delaet	Insider	Sell	1,091	$135.00	$147,285.00	2,507
11/29/2024	Jude Onyia	Insider	Sell	2,331	$126.29	$294,381.99	15,449
8/15/2024	William H. Rastetter	Director	Sell	14,250	$146.69	$2,090,332.50	37,491
8/13/2024	Gary A. Lyons	Director	Sell	11,570	$150.43	$1,740,475.10	119,047
8/13/2024	Ingrid Delaet	Insider	Sell	7,143	$150.10	$1,072,164.30	2,507
8/13/2024	Matt Abernethy	CFO	Sell	14,100	$150.38	$2,120,358.00	31,528
8/6/2024	Ingrid Delaet	Insider	Sell	273	$147.70	$40,322.10	6,607
8/1/2024	Julie Cooke	Insider	Sell	12,632	$153.26	$1,935,980.32	18,202
7/16/2024	Gary A. Lyons	Director	Sell	930	$150.03	$139,527.90	119,047
7/16/2024	Julie Cooke	Insider	Sell	900	$150.04	$135,036.00	18,202
7/1/2024	Julie Cooke	Insider	Sell	10,000	$140.19	$1,401,900.00	18,202
5/29/2024	Stephen A. Sherwin	Director	Sell	40,000	$133.46	$5,338,400.00	26,504
5/17/2024	Shalini Sharp	Director	Sell	1,106	$141.90	$156,941.40	994
5/15/2024	Matt Abernethy	CFO	Sell	15,000	$140.24	$2,103,600.00	31,528
5/14/2024	Gary A. Lyons	Director	Sell	12,500	$135.63	$1,695,375.00	116,947
5/6/2024	Ingrid Delaet	Insider	Sell	273	$140.55	$38,370.15	7,507
4/15/2024	Eric Benevich	Insider	Sell	19,818	$133.36	$2,642,928.48	40,778
3/21/2024	Ingrid Delaet	Insider	Sell	5,000	$145.06	$725,300.00	7,507
3/14/2024	Eric Benevich	Insider	Sell	75,000	$139.38	$10,453,500.00	40,778
3/14/2024	George J. Morrow	Director	Sell	40,000	$139.42	$5,576,800.00
3/11/2024	Ingrid Delaet	Insider	Sell	200	$140.00	$28,000.00	7,507
3/11/2024	Richard F. Pops	Director	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Ingrid Delaet	Insider	Sell	1,800	$140.03	$252,054.00	7,507
3/8/2024	Richard F. Pops	Director	Sell	1,700	$140.05	$238,085.00	29,512
2/29/2024	Ingrid Delaet	Insider	Sell	273	$135.51	$36,994.23	7,507
2/27/2024	Leslie V. Norwalk	Director	Sell	8,000	$135.67	$1,085,360.00
2/20/2024	Richard F. Pops	Director	Sell	15,000	$132.47	$1,987,050.00	29,512
2/13/2024	Eiry Roberts	Insider	Sell	1,114	$132.96	$148,117.44	23,716
2/13/2024	Kevin Charles Gorman	CEO	Sell	2,832	$133.02	$376,712.64	514,596
2/13/2024	Matt Abernethy	CFO	Sell	1,352	$132.85	$179,613.20	31,528
2/8/2024	David W. Boyer	Insider	Sell	1,328	$135.41	$179,824.48	4,895
2/8/2024	Kevin Charles Gorman	CEO	Sell	2,274	$134.15	$305,057.10	506,962
2/8/2024	Matt Abernethy	CFO	Sell	980	$134.21	$131,525.80	30,314
2/6/2024	David W. Boyer	Insider	Sell	456	$141.96	$64,733.76	4,894
2/6/2024	Kevin Charles Gorman	CEO	Sell	3,040	$142.18	$432,227.20	504,919
2/6/2024	Matt Abernethy	CFO	Sell	1,280	$142.19	$182,003.20	29,434
1/31/2024	Eiry Roberts	Insider	Sell	1,457	$140.79	$205,131.03	20,832
1/31/2024	Kevin Charles Gorman	CEO	Sell	2,707	$140.69	$380,847.83	502,188
1/31/2024	Matt Abernethy	CFO	Sell	1,283	$140.72	$180,543.76	28,284
1/22/2024	Darin Lippoldt	Insider	Sell	10,000	$139.86	$1,398,600.00	35,882
1/8/2024	Kevin Charles Gorman	CEO	Sell	105,835	$132.44	$14,016,787.40	499,754
1/2/2024	Kyle Gano	Insider	Sell	75,000	$131.47	$9,860,250.00	130,250
1/2/2024	William H. Rastetter	Director	Sell	11,044	$131.47	$1,451,954.68	51,741
12/22/2023	Eiry Roberts	Insider	Sell	10,000	$126.74	$1,267,400.00	19,521
12/12/2023	Eiry Roberts	Insider	Sell	13,925	$120.30	$1,675,177.50	29,521
12/8/2023	Eiry Roberts	Insider	Sell	300	$120.10	$36,030.00	29,521
12/6/2023	Darin Lippoldt	Insider	Sell	20,830	$119.86	$2,496,683.80	35,882
12/1/2023	Gary A. Lyons	Director	Sell	5,000	$116.77	$583,850.00	203,697
11/29/2023	Jude Onyia	Insider	Sell	2,331	$113.57	$264,731.67	11,732
11/27/2023	Darin Lippoldt	Insider	Sell	10,919	$112.27	$1,225,876.13	35,882
10/2/2023	David W. Boyer	Insider	Sell	1,437	$112.68	$161,921.16	4,894
9/12/2023	Gary A. Lyons	Director	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Gary A. Lyons	Director	Sell	5,000	$110.06	$550,300.00	203,697
9/1/2023	Julie Cooke	Insider	Sell	824	$110.93	$91,406.32	17,263
8/30/2023	David W. Boyer	Insider	Sell	2,733	$107.60	$294,070.80	3,460
8/28/2023	Ingrid Delaet	Insider	Sell	1,431	$107.52	$153,861.12	5,931
8/21/2023	Jude Onyia	Insider	Sell	3,198	$107.37	$343,369.26	9,638
8/21/2023	Kevin Charles Gorman	CEO	Sell	9,328	$107.40	$1,001,827.20	499,754
8/21/2023	Matt Abernethy	CFO	Sell	2,132	$107.39	$228,955.48	27,131
5/1/2023	Julie Cooke	Insider	Sell	11,397	$103.89	$1,184,034.33	16,169
5/1/2023	William H. Rastetter	Director	Sell	4,300	$101.43	$436,149.00	42,785
4/24/2023	Eiry Roberts	Insider	Sell	14,400	$103.48	$1,490,112.00	26,644
4/21/2023	William H. Rastetter	Director	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	William H. Rastetter	Director	Sell	903	$105.00	$94,815.00	34,729
2/23/2023	Neurocrine Biosciences Inc	Major Shareholder	Buy	4,395,588	$8.88	$39,032,821.44	8,575,316
2/8/2023	Eric Benevich	Insider	Sell	980	$104.12	$102,037.60	34,381
2/8/2023	Kevin Charles Gorman	CEO	Sell	2,274	$104.30	$237,178.20	491,365
2/7/2023	Matt Abernethy	CFO	Sell	26,328	$102.40	$2,695,987.20	24,333
2/6/2023	Eric Benevich	Insider	Sell	1,280	$105.63	$135,206.40	17,879
2/6/2023	Kevin Charles Gorman	CEO	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Eiry Roberts	Insider	Sell	1,457	$109.99	$160,255.43	26,171
1/31/2023	Kevin Charles Gorman	CEO	Sell	2,707	$110.08	$297,986.56	465,278
1/31/2023	Matt Abernethy	CFO	Sell	1,283	$109.98	$141,104.34	21,357
1/6/2023	Eric Benevich	Insider	Sell	400	$125.00	$50,000.00	15,643
1/3/2023	Stephen A. Sherwin	Director	Sell	30,000	$118.86	$3,565,800.00	25,055

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

92.59% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/2/2025	Allworth Financial LP	5,009	$0.70M	0.0%	+68.1%	0.005%
12/2/2025	IFP Advisors Inc	2,475	$0.35M	0.0%	+14.0%	0.002%
12/2/2025	Swiss Life Asset Management Ltd	17,767	$2.49M	0.0%	+31.9%	0.018%
11/24/2025	CIBC Private Wealth Group LLC	7,981	$1.12M	0.0%	+17,250.0%	0.008%
11/21/2025	CIBC Bancorp USA Inc.	3,548	$0.50M	0.0%	N/A	0.004%
11/20/2025	Caerus Investment Advisors LLC	4,733	$0.66M	0.3%	N/A	0.005%
11/19/2025	Captrust Financial Advisors	28,051	$3.94M	0.0%	+130.4%	0.028%
11/19/2025	Coldstream Capital Management Inc.	4,090	$0.57M	0.0%	+8.3%	0.004%
11/19/2025	Danske Bank A S	43,416	$6.10M	0.0%	N/A	0.044%
11/18/2025	Silvant Capital Management LLC	19,947	$2.80M	0.1%	-8.6%	0.020%
11/17/2025	Peloton Wealth Strategists	13,810	$1.94M	0.8%	-7.4%	0.014%
11/17/2025	Jacobs Levy Equity Management Inc.	35,520	$4.99M	0.0%	-34.2%	0.036%
11/17/2025	NewEdge Advisors LLC	12,326	$1.73M	0.0%	+14.9%	0.012%
11/17/2025	Armistice Capital LLC	697,022	$97.85M	1.5%	+3.1%	0.699%
11/17/2025	CANADA LIFE ASSURANCE Co	72,989	$10.23M	0.0%	-2.9%	0.073%
11/17/2025	Utah Retirement Systems	15,981	$2.24M	0.0%	-2.0%	0.016%
11/17/2025	Virtus Advisers LLC	2,584	$0.36M	0.2%	+297.5%	0.003%
11/17/2025	Voleon Capital Management LP	18,292	$2.57M	0.1%	N/A	0.018%
11/17/2025	Verition Fund Management LLC	38,673	$5.43M	0.0%	-19.6%	0.039%
11/17/2025	State Street Corp	4,346,479	$610.16M	0.0%	-2.7%	4.359%
11/17/2025	Public Employees Retirement System of Ohio	32,956	$4.63M	0.0%	+0.7%	0.033%
11/17/2025	Palo Alto Investors LP	18,117	$2.54M	0.5%	+35.9%	0.018%
11/17/2025	Parkman Healthcare Partners LLC	141,822	$19.91M	2.1%	-14.6%	0.142%
11/17/2025	Nomura Holdings Inc.	9,151	$1.29M	0.0%	+98.5%	0.009%
11/17/2025	Northwestern Mutual Wealth Management Co.	207	$29K	0.0%	-66.9%	0.000%
11/17/2025	Northern Trust Corp	925,714	$129.95M	0.0%	-0.4%	0.928%
11/17/2025	Mariner LLC	54,792	$7.69M	0.0%	+102.7%	0.055%
11/17/2025	Mercer Global Advisors Inc. ADV	31,602	$4.44M	0.0%	+126.4%	0.032%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	12,728	$1.79M	0.0%	-3.1%	0.013%
11/17/2025	Knollwood Investment Advisory LLC	6,527	$0.92M	0.1%	-1.2%	0.007%
11/17/2025	Integrated Wealth Concepts LLC	8,149	$1.14M	0.0%	+87.2%	0.008%
11/17/2025	Iron Triangle Partners LP	131,390	$18.45M	2.6%	N/A	0.132%
11/17/2025	Holocene Advisors LP	5,209	$0.73M	0.0%	N/A	0.005%
11/17/2025	Gotham Asset Management LLC	136,354	$19.14M	0.1%	+49.6%	0.137%
11/17/2025	Fred Alger Management LLC	2,122	$0.30M	0.0%	+5.6%	0.002%
11/17/2025	Focus Partners Wealth	65,822	$9.24M	0.0%	+15.1%	0.066%
11/17/2025	Distillate Capital Partners LLC	94,416	$13.26M	0.7%	-22.4%	0.095%
11/17/2025	Brevan Howard Capital Management LP	3,884	$0.55M	0.0%	-75.2%	0.004%
11/17/2025	Azimuth Capital Investment Management LLC	70,678	$9.92M	0.4%	-1.8%	0.071%
11/17/2025	Banco Bilbao Vizcaya Argentaria S.A.	147,789	$20.75M	0.2%	-0.1%	0.148%
11/17/2025	California Public Employees Retirement System	194,157	$27.26M	0.0%	+12.0%	0.195%
11/17/2025	Bank of Nova Scotia	6,366	$0.89M	0.0%	+21.6%	0.006%
11/17/2025	Boone Capital Management LLC	166,414	$23.36M	7.7%	-7.7%	0.167%
11/17/2025	Braidwell LP	880,282	$123.57M	3.7%	-24.1%	0.883%
11/17/2025	Algert Global LLC	2,370	$0.33M	0.0%	N/A	0.002%
11/17/2025	Alliancebernstein L.P.	618,129	$86.77M	0.0%	+5.8%	0.620%
11/17/2025	Ameriprise Financial Inc.	614,577	$86.27M	0.0%	+38.7%	0.616%
11/14/2025	Schonfeld Strategic Advisors LLC	77,693	$10.91M	0.1%	+6.5%	0.078%
11/14/2025	Creative Planning	32,466	$4.56M	0.0%	+127.9%	0.033%
11/14/2025	Lazard Asset Management LLC	40,877	$5.74M	0.0%	+12.4%	0.041%
11/14/2025	AQR Capital Management LLC	2,773,648	$388.44M	0.2%	+83.7%	2.782%
11/14/2025	Credit Agricole S A	7,611	$1.07M	0.0%	N/A	0.008%
11/14/2025	Raymond James Financial Inc.	566,937	$79.59M	0.0%	-28.4%	0.569%
11/14/2025	Bellevue Group AG	1,763,105	$247.51M	5.1%	-3.1%	1.768%
11/14/2025	Virtu Financial LLC	1,757	$0.25M	0.0%	N/A	0.002%
11/14/2025	Amundi	230,263	$32.11M	0.0%	+5.0%	0.231%
11/14/2025	Freestone Grove Partners LP	132,338	$18.58M	0.1%	-21.3%	0.133%
11/14/2025	Deerfield Management Company L.P.	1,184,345	$166.26M	2.5%	+1.4%	1.188%
11/14/2025	Man Group plc	80,832	$11.35M	0.0%	+71.2%	0.081%
11/14/2025	Orbimed Advisors LLC	353,640	$49.64M	1.2%	-19.4%	0.355%
11/14/2025	California State Teachers Retirement System	136,950	$19.23M	0.0%	+1.2%	0.137%
11/14/2025	Horizon Investments LLC	38,616	$5.42M	0.1%	+297.6%	0.039%
11/14/2025	Zurcher Kantonalbank Zurich Cantonalbank	67,369	$9.46M	0.0%	-1.3%	0.068%
11/14/2025	Balyasny Asset Management L.P.	203,407	$28.55M	0.0%	N/A	0.204%
11/14/2025	Brooklyn Investment Group	2,945	$0.41M	0.0%	+45.1%	0.003%
11/14/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	765,237	$107.42M	0.0%	-44.9%	0.767%
11/14/2025	Tower Research Capital LLC TRC	5,298	$0.74M	0.0%	+84.4%	0.005%
11/14/2025	Two Sigma Investments LP	347,565	$48.79M	0.1%	N/A	0.349%
11/14/2025	Ossiam	2,201	$0.31M	0.0%	-26.4%	0.002%
11/14/2025	Squarepoint Ops LLC	40,481	$5.68M	0.0%	-75.7%	0.041%
11/14/2025	2Xideas AG	50,797	$7.13M	1.5%	-25.1%	0.051%
11/14/2025	Towarzystwo Funduszy Inwestycyjnych PZU SA	391	$55K	0.0%	-78.0%	0.000%
11/14/2025	iSAM Funds UK Ltd	6,632	$0.93M	0.2%	+103.5%	0.007%
11/14/2025	Wellington Management Group LLP	1,811,762	$254.34M	0.0%	-10.7%	1.817%
11/14/2025	NorthRock Partners LLC	2,890	$0.41M	0.0%	N/A	0.003%
11/14/2025	Comerica Bank	29,592	$4.15M	0.0%	-7.0%	0.030%
11/14/2025	Dodge & Cox	5,556,618	$780.04M	0.4%	-0.2%	5.573%
11/14/2025	Glenmede Investment Management LP	82,577	$11.59M	0.1%	-1.9%	0.083%
11/13/2025	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	14,224	$2M	0.0%	-8.6%	0.014%
11/13/2025	Marshall Wace LLP	97,289	$13.66M	0.0%	+133.6%	0.098%
11/13/2025	Aware Super Pty Ltd as trustee of Aware Super	108,364	$15.21M	0.2%	+186.7%	0.109%
11/13/2025	Kennedy Capital Management LLC	56,269	$7.90M	0.2%	+5.2%	0.056%
11/13/2025	Quadrature Capital Ltd	11,376	$1.60M	0.0%	-23.2%	0.011%
11/13/2025	Arrowstreet Capital Limited Partnership	411,660	$57.79M	0.0%	+228.9%	0.413%
11/13/2025	Invesco Ltd.	323,611	$45.43M	0.0%	+11.9%	0.325%
11/13/2025	Employees Retirement System of Texas	1,059	$0.15M	0.0%	N/A	0.001%
11/13/2025	Sei Investments Co.	300,195	$42.14M	0.0%	+36.0%	0.301%
11/13/2025	UBS Group AG	364,572	$51.18M	0.0%	-40.7%	0.366%
11/13/2025	Connor Clark & Lunn Investment Management Ltd.	281,113	$39.46M	0.1%	+13.1%	0.282%
11/13/2025	Capital Fund Management S.A.	123,704	$17.37M	0.0%	-39.3%	0.124%
11/13/2025	BNP Paribas Financial Markets	100,975	$14.18M	0.0%	-11.6%	0.101%
11/13/2025	DE Burlo Group Inc.	4,767	$0.67M	0.1%	+2.1%	0.005%
11/13/2025	Mackenzie Financial Corp	84,874	$11.92M	0.0%	+12.1%	0.085%
11/13/2025	Franklin Resources Inc.	634,965	$89.14M	0.0%	-9.7%	0.637%
11/13/2025	Magnetar Financial LLC	34,071	$4.78M	0.0%	N/A	0.034%
11/13/2025	Silvant Capital Management LLC	19,947	$2.80M	0.1%	-8.6%	0.020%
11/13/2025	Quadrant Capital Group LLC	8,258	$1.16M	0.0%	+8.3%	0.008%
11/13/2025	Van ECK Associates Corp	95,097	$13.35M	0.0%	-11.8%	0.095%
11/13/2025	Legal & General Group Plc	400,170	$56.18M	0.0%	+0.2%	0.401%
11/13/2025	Vestcor Inc	22,744	$3.19M	0.1%	+5.7%	0.023%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $154.63

$153.38

$156.00

50 Day Range

MA: $143.45

$136.63

$154.80

52 Week Range

Now: $154.63

$84.23

$157.67

Volume

81,134 shs

Average Volume

1,150,993 shs

Market Capitalization

$15.42 billion

P/E Ratio

36.99

Dividend Yield

N/A

Beta

0.27

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Kevin Charles Gorman (Director)
Kevin Charles Gorman (CEO)
Kyle Gano (CEO)
Kyle Gano (Insider)
Gary A Lyons (Director)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
George J Morrow (Director)
David W Boyer (Insider)
Shalini Sharp (Director)
George J Morrow (Director)
Leslie V Norwalk (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
Vanguard Group Inc. — 9.74%
Dodge & Cox — 5.57%
JPMorgan Chase & Co. — 4.74%
State Street Corp — 4.36%
AQR Capital Management LLC — 2.78%
Wellington Management Group LLP — 1.82%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC
Braidwell LP
UBS Group AG
Raymond James Financial Inc.
Wellington Management Group LLP
Thrivent Financial for Lutherans
Squarepoint Ops LLC
State Street Corp
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Kevin Charles Gorman (Director)
Kevin Charles Gorman (CEO)
Kyle Gano (CEO)
Kyle Gano (Insider)
Gary A Lyons (Director)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
AQR Capital Management LLC
JPMorgan Chase & Co.
Two Sigma Investments LP
Arrowstreet Capital Limited Partnership
Balyasny Asset Management L.P.
Ameriprise Financial Inc.
Iron Triangle Partners LP
Rakuten Investment Management Inc.